(2 October 2024, Hong Kong) Fosun International Limited (HKEX stock code: 00656, “FosunInternational”, “Fosun” or “the Company”) has successfully completed asustainability-linked syndicated loan amounting to USD888 million. The loan wasinitially launched earlier this year in May with first close of USD603 million,followed by Greenshoe accessions. The final size r

Fosun International Announces 2024 Interim Results: Powered by Core Strengths, Focus on Core Businesses and Reinforce Organic Growth Momentum 2024 Interim Results Highlights:·Total revenue maintained growth, reaching RMB97.84 billion;·Industrial operation profit maintained growth, reaching RMB3.47 billion;·Continued focus on core businesses, with the four core subsi

(August 27, 2024, Shanghai China) On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH; 02196.HK),announced its operating performance for the first half of 2024 (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue of RMB20.46 billion, an increase of 5.31% Y

Shanghai, China, August 26, 2024 – Henlius (2696.HK) announced its 2024 interim results. During the reporting period, Henlius’ revenue reached about RMB2.7461 billion, representing an increase of 9.8% YoY, and recorded a net profit of RMB386.3 million, up by 61.0% YoY. The solid and sustained profitability is due to increasing commercial sales

(Hong Kong, Shanghai, 27 March 2024) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its annual results for the year ended 31 December 2023 (the “Reporting Period”).During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion&#x

Results Highlights• Business Volume1reached RMB18,125.1 million, with a year-on-year growth of 19%, surpassing the 28% recorded in 2019, while revenue increased by 24% year-on-year to RMB17,151.8 million•Profit attributable to equity holders turned around to RMB307.2 million• Club Med achieved a Business Volume of RMB15,122.5 million, representing a 19% year-on-